Ziarco Pharma Ltd: Appointment of Dr. Arvind Hundal as Chief Business Officer
DISCOVERY PARK, SANDWICH, England–(BUSINESS WIRE)– Ziarco Pharma Ltd. (“Ziarco” or “the Company”), a biopharmaceutical company focusing on the development of novel drugs for the treatment of inflammatory skin disorders, today announced the appointment of Dr Arvind Hundal as its Chief Business Officer (CBO), effective immediately.
Dr Hundal will lead the Company’s corporate development and business development efforts, and will serve as a member of the Company’s executive leadership team. Arvind is a skilled executive with more than 20 years’ involvement in international private and public biotechnology companies. She has extensive transaction experience covering licensing, acquisition, spin-out and IPO.
Commenting on the appointment, Mike Grey, Executive Chairman of Ziarco said: “We are extremely pleased to have attracted Arvind to Ziarco and welcome the wealth of business development experience within the international life sciences industry that she brings with her. The appointment of a CBO comes at a significant time for Ziarco as we eagerly await the data from our Phase II study in atopic dermatitis.”
Arvind Hundal added: “I am thrilled to be joining Ziarco, at such an exciting time. ZPL-389 is close to completing a proof of concept clinical trial in atopic dermatitis and has the potential to be a first in class oral treatment for atopic dermatitis and other inflammatory skin disorders. I look forward to working with the team to help maximise the value of the Company’s whole pipeline as we enter this important period.”
Ends
About Ziarco
Ziarco is a clinical-stage biotechnology company developing innovative therapeutics targeting dermatological and inflammatory diseases. ZPL-389, the Company’s lead compound, is an oral histamine H4 receptor antagonist, currently in two Phase 2a studies: the first in atopic dermatitis is fully recruited and will read out in Q2 2016; and the second has been initiated in moderate to severe psoriasis patients and is expected to be fully recruited in Q1 2017.
ZPL-521, a topical cPLA2 inhibitor, is being developed for moderate to severe inflammatory skin diseases and is targeted to start a clinical study in atopic dermatitis in mid-2016, with data due in Q1 2017.
Ziarco’s investors include Biotechnology Value Fund L.P. and other affiliates of BVF Partners L.P., Pfizer Venture Investments, New Enterprise Associates, Lundbeckfond Ventures and Amgen Ventures. Founded in October 2012, the Company is based in Discovery Park, Sandwich, UK. For more information please visit www.ziarcopharma.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160228005016/en/
Contacts
For further information, please contact:
Ziarco Pharma Ltd
Arvind Hundal
arvind.hundal@ziarcopharma.com< br/>or
Consilium Strategic Communications
Mary-Jane Elliott / Ivar Milligan
+44 (0)20 3709 5700
ziarco@consilium-comms.com